Abstract:Fibroblast growth factor 21 (FGF-21) is a member of FGF family. Recently, it is discovered as a non-insulin-dependent cytokine to regulate blood glucose and a potential drug candidate for treatment of type 2 diabetes mellitus. However, the stability of FGF-21 is poor and its half-life in vivo is short, which severely affect its application in clinical practice. In order to solve this problem, the N-terminus of mFGF-21 was PEGylated in a site-specific manner by methoxy poly-ethylene glycol (mPEG) propionaldehydes with an average molecular mass of 20 ku for improving its biological properties including increasing half-life in vivo, and decreasing immunogenicity. The effects of pH, reaction time, protein concentrations and mass ratio between the reactants on the PEGylation of mFGF-21 were analyzed. PEG-mFGF-21 was isolated by Capto Q anion exchange chromatography or Superdex 75 gel filtration chromatography. As a result, the optimal reaction, method for mFGF-21 PEGylation and purification processes of PEG-mFGF-21 were established. Then we study the physical and chemical properties, immunogenicity, in vivo half-life, in vitro biological activity and in vivo hypoglycemic effects of PEG-mFGF-21. We found that the temperature stability and anti-protease ability of mFGF-21 were significantly improved after PEGylation. The indirect ELISA results for detection of serum antibody levels against mFGF-21 and the target protein concentration showed that PEGlyation of mFGF-21 significantly reduced its immunogenicity and increased its half-life in vivo. The glucose uptake assay results in HepG2 cells demonstrated that the in vitro activity of PEG-mFGF-21 did not decline. However, with the increment of stimulating time, the glucose uptake in cells treated with PEG-mFGF-21 significantly increased than mFGF-21. The experimental results of short-term blood glucose regulation in type 2 diabetic animals showed that the hypoglycemic speed of mFGF-21 was faster than PEG-mFGF-21, but it lasted shorter. The long-term blood glucose regulation experimental results showed that PEG-mFGF-21 had better hypoglycemic effect than mFGF-21. Surprisingly, blood glucose of PEG-mFGF-21-treated mice remained at low level for several days after the drug was withdrawn. In conclusion, under the premise of remaining its biological activity in vitro, PEGylation of mFGF-21 can improve its physical stability and anti-protease ability, decrease its immunogenicity and increase its in vivo half-life. It can also prolong the hypoglycemic effect of mFGF-21 in diabetic animals. This study provides an important technology platform for drug development of FGF-21.

Therapeutic Effect of Long-Acting FGF21 with Controlled Site-Specific Modification on Nonalcoholic Steatohepatitis

Enhanced Bioactivity and Stability of a Long-Acting FGF21: A Novel Variant for the Treatment of NASH

Lipidation-dimerization Platform Unlocks Treatment Potential of Fibroblast Growth Factor 21 for Non-Alcoholic Steatohepatitis

A Long-Acting FGF21 Alleviates Hepatic Steatosis and Inflammation in a Mouse Model of Non-Alcoholic Steatohepatitis Partly Through an FGF21-adiponectin-IL17A Pathway.

Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis

Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation

The Hypoglycemic Effect of the Pegylated Fgf-21

Long-lasting hypoglycemic effect of modified FGF-21 analog with polyethylene glycol in type 1 diabetic mice and its systematic toxicity

Enhanced Expression and Distinctive Characterization of a Long-Acting FGF21 and Its Potential to Alleviate Nonalcoholic Steatohepatitis

A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis

[Therapeutic Effect of Fibroblast Growth Factor 21 on NAFLD in MSG-iR Mice and Its Mechanism].

A Better Anti-Diabetic Recombinant Human Fibroblast Growth Factor 21 (Rhfgf21) Modified With Polyethylene Glycol

FGF21 Ameliorates Nonalcoholic Fatty Liver Disease by Inducing Autophagy

Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice

FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis

The Effects of B1344, a Novel Fibroblast Growth Factor 21 Analog, on Nonalcoholic Steatohepatitis in Nonhuman Primates

[Role and mechanism of action of fibroblast growth factor-21 in reducing triglyceride in nonalcoholic fatty liver disease].

Pilot-scale Production and Characterization of PEGylated Human FGF-21 Analog.

Stability and Glucose Regulation of FGF21 after Modified with Arginines*

A long‐acting FGF21 attenuates metabolic dysfunction‐associated steatohepatitis‐related fibrosis by modulating NR4A1‐mediated Ly6C phenotypic switch in macrophages

Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease